CA3107109A1 - Enantiomerically purified gper agonist for use in treating disease states and conditions - Google Patents
Enantiomerically purified gper agonist for use in treating disease states and conditions Download PDFInfo
- Publication number
- CA3107109A1 CA3107109A1 CA3107109A CA3107109A CA3107109A1 CA 3107109 A1 CA3107109 A1 CA 3107109A1 CA 3107109 A CA3107109 A CA 3107109A CA 3107109 A CA3107109 A CA 3107109A CA 3107109 A1 CA3107109 A1 CA 3107109A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- srr
- derivative
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701726P | 2018-07-21 | 2018-07-21 | |
| US62/701,726 | 2018-07-21 | ||
| PCT/US2019/042827 WO2020023391A1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107109A1 true CA3107109A1 (en) | 2020-01-30 |
Family
ID=69160978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107109A Pending CA3107109A1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20200024262A1 (https=) |
| EP (2) | EP3823617B1 (https=) |
| JP (2) | JP2021532148A (https=) |
| KR (1) | KR20210049778A (https=) |
| CN (1) | CN112469409B (https=) |
| AU (1) | AU2019310029B2 (https=) |
| BR (1) | BR112021001031A2 (https=) |
| CA (1) | CA3107109A1 (https=) |
| DK (1) | DK3823617T3 (https=) |
| ES (1) | ES2980434T3 (https=) |
| FI (1) | FI3823617T3 (https=) |
| HR (1) | HRP20240661T1 (https=) |
| HU (1) | HUE067185T2 (https=) |
| IL (2) | IL312938A (https=) |
| LT (1) | LT3823617T (https=) |
| MX (2) | MX2021000809A (https=) |
| NZ (1) | NZ771952A (https=) |
| PL (1) | PL3823617T3 (https=) |
| PT (1) | PT3823617T (https=) |
| RS (1) | RS65599B1 (https=) |
| SI (1) | SI3823617T1 (https=) |
| SM (1) | SMT202400205T1 (https=) |
| WO (1) | WO2020023391A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022091029A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| US20240376547A1 (en) * | 2021-04-08 | 2024-11-14 | Linnaeus Therapeutics, Inc. | Oncologic variations associated with cancer and methods of treatment |
| WO2022245899A2 (en) * | 2021-05-19 | 2022-11-24 | Linaeus Therapeutics, Inc. | Diagnostic methods and compositions for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US251870A (en) * | 1882-01-03 | Automatic gate | ||
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| US7875721B2 (en) * | 2005-08-04 | 2011-01-25 | Stc.Unm | Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
| WO2008153945A2 (en) * | 2007-06-06 | 2008-12-18 | University Of South Florida | Nutraceutical co-crystal compositions |
| MX382354B (es) * | 2010-11-01 | 2025-03-13 | Celgene Car Llc | Compuestos heterocíclicos y usos de los mismos. |
| US10251870B2 (en) * | 2015-03-06 | 2019-04-09 | Stc.Unm | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity |
| AU2016246688B2 (en) * | 2015-04-06 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject |
| US11369618B2 (en) | 2016-06-17 | 2022-06-28 | The Trustees Of The University Of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
-
2019
- 2019-07-22 ES ES19842049T patent/ES2980434T3/es active Active
- 2019-07-22 BR BR112021001031-9A patent/BR112021001031A2/pt unknown
- 2019-07-22 US US16/518,516 patent/US20200024262A1/en not_active Abandoned
- 2019-07-22 IL IL312938A patent/IL312938A/en unknown
- 2019-07-22 PT PT198420499T patent/PT3823617T/pt unknown
- 2019-07-22 HU HUE19842049A patent/HUE067185T2/hu unknown
- 2019-07-22 JP JP2021504360A patent/JP2021532148A/ja active Pending
- 2019-07-22 PL PL19842049.9T patent/PL3823617T3/pl unknown
- 2019-07-22 SM SM20240205T patent/SMT202400205T1/it unknown
- 2019-07-22 AU AU2019310029A patent/AU2019310029B2/en active Active
- 2019-07-22 CA CA3107109A patent/CA3107109A1/en active Pending
- 2019-07-22 EP EP19842049.9A patent/EP3823617B1/en active Active
- 2019-07-22 FI FIEP19842049.9T patent/FI3823617T3/fi active
- 2019-07-22 RS RS20240634A patent/RS65599B1/sr unknown
- 2019-07-22 NZ NZ771952A patent/NZ771952A/en unknown
- 2019-07-22 WO PCT/US2019/042827 patent/WO2020023391A1/en not_active Ceased
- 2019-07-22 CN CN201980048925.4A patent/CN112469409B/zh active Active
- 2019-07-22 LT LTEPPCT/US2019/042827T patent/LT3823617T/lt unknown
- 2019-07-22 EP EP24161261.3A patent/EP4356913A3/en not_active Withdrawn
- 2019-07-22 KR KR1020217002117A patent/KR20210049778A/ko not_active Ceased
- 2019-07-22 DK DK19842049.9T patent/DK3823617T3/da active
- 2019-07-22 SI SI201930756T patent/SI3823617T1/sl unknown
- 2019-07-22 HR HRP20240661TT patent/HRP20240661T1/hr unknown
- 2019-07-22 IL IL280283A patent/IL280283B2/en unknown
- 2019-07-22 MX MX2021000809A patent/MX2021000809A/es unknown
- 2019-11-13 US US16/682,821 patent/US10934277B2/en active Active
-
2021
- 2021-01-20 MX MX2024008188A patent/MX2024008188A/es unknown
- 2021-02-25 US US17/184,870 patent/US11760749B2/en active Active
- 2021-05-24 US US17/328,590 patent/US20220089576A1/en not_active Abandoned
-
2023
- 2023-08-03 US US18/364,690 patent/US20230382896A1/en not_active Abandoned
-
2024
- 2024-05-29 JP JP2024087006A patent/JP2024119868A/ja active Pending
- 2024-06-24 US US18/752,146 patent/US20250171421A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250171421A1 (en) | Enantiomerically purified gper agonist for use in treating disease states and conditions | |
| AU2017281903B2 (en) | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | |
| JP2022071072A (ja) | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 | |
| US11098057B2 (en) | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof | |
| US20220372044A1 (en) | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea | |
| JP6908536B2 (ja) | ムスカリンｍ２受容体の正のアロステリックモジュレーター | |
| KR102805250B1 (ko) | Mtorc1 조절제 및 이의 용도 | |
| CN110234638A (zh) | 杂芳基苯氧基苯甲酰胺kappa阿片类配体 | |
| JP2024509437A (ja) | 新規ベンズアゼピン縮合環式誘導体 | |
| WO2021226020A1 (en) | Polymorphic forms of (r)-oxybutynin hydrochloride | |
| US20070197609A1 (en) | Salts of inducible nitric oxide synthase dimerization inhibitors | |
| WO2019242642A1 (zh) | 一种otr抑制剂的可药用盐、晶型及制备方法 | |
| WO2026082108A1 (zh) | 一种nlrp3抑制剂用于治疗帕金森病或帕金森综合征的用途 | |
| KR20190131017A (ko) | 선택적 오로라 a 키나아제 억제제 | |
| WO2026082102A1 (zh) | 一种nlrp3抑制剂用于治疗脑血管疾病的用途 | |
| EP4146621A1 (en) | Polymorphic forms of (r)-oxybutynin hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240722 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240722 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250626 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250721 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250814 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251121 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260108 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260108 |